Study Results: Mesoblast’s Cell Therapy in Degenerative Disc Disease

Studies suggest that a single intra-discal injection of 6 million Mesenchymal Precursor Cells (MPCs) resulted in meaningful improvements in chronic low back pain (CLBP) and function that were durable for at least 36 months.

Mesoblast announced the results from a randomized, placebo-controlled 100-patient Phase II trial of its...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us